Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 3/20 | 0.50 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25401634 | 0.81 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL207440 | 0.79 | KDM4E (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28150624 | 0.79 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3090701 | 0.79 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27676255 | 0.79 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29501241 | 0.79 | KDM4E (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4159665 | 0.79 | ALDH1A1 (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6280901 | 0.78 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6280908 | 0.78 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29220454 | 0.77 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081864-A | Synthesis method of 1, 3-diboron compound | 西安交通大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120081864-A | Synthesis method of 1, 3-diboron compound | 西安交通大学 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024022314-A1 | TRIAZOLE COMPOUNDS AND USE THEREOF AS LPAR1 ANTAGONIST | 武汉人福创新药物研发中心有限公司 | 2024-02-01 | — | — | WO | disclosed |
| CN-117447450-A | Triazole compounds and their use as LPAR1 antagonists | 武汉人福创新药物研发中心有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-112125770-B | Silicon-center chiral dihydrobenzothiole and preparation method thereof | 南方科技大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022073905-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022073905-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| CN-114126597-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3906024-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-112125770-A | Silicon-center chiral dihydrobenzothiole and preparation method thereof | 南方科技大学 | 2020-12-25 | — | — | CN | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | TUBB4A 730/4885TUBB 1669/4885TUBA3C 507/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | TUBB4A 730/4885TUBB 1669/4885TUBA3C 507/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | TUBB4A 1549/4885TUBB 1123/4885TUBA3C 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.